Weill Medical College Of Cornell University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1865-01-01

Employees: -

Market Cap: -

Website: http://weill.cornell.edu

Clinical Trials

A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

Phase 2

Completed

Conditions: Myeloproliferative Neoplasms

Interventions: Drug: SGI-110

First Posted Date: 2017-03-09

Last Posted Date: 2022-05-05

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 22

Registration Number: NCT03075826

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Endoscopic Resection Multicenter Registry

Conditions: Gastrointestinal Neoplasms
Neoplasms
Esophageal Neoplasms
Duodenal Polyp
Stomach Neoplasm
Gastric Cancer
Gastric Neoplasm
Gastrointestinal Disease
Duodenal Neoplasms
Stomach Polyp

Interventions: Procedure: Endoscopic Resection

First Posted Date: 2017-02-27

Last Posted Date: 2017-04-25

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 200

Registration Number: NCT03065257

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

EUS BD vs ERCP TP for Pancreatic Cancer

Not Applicable

Conditions: Biliary Duct Obstruction
Periampullary Cancer
Unresectable Pancreatic Cancer
Periampullary Carcinoma Non-Resectable
Pancreatic Cancer
Pancreatic Adenocarcinoma
Biliary Tract Neoplasms

Interventions: Procedure: ERCP
Procedure: Endoscopic Ultrasound Guided Biliary Drainage

First Posted Date: 2017-02-24

Last Posted Date: 2017-02-24

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 120

Registration Number: NCT03063554

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial Biomarkers

Phase 2

Completed

Conditions: Parkinson Disease

Interventions: Dietary Supplement: Placebo
Drug: Ubiquinol

First Posted Date: 2017-02-23

Last Posted Date: 2017-05-23

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 11

Registration Number: NCT03061513

Problem Adaptation Therapy for Mild Cognitive Impairment and Depression

Not Applicable

Completed

Conditions: Depression
Cognitive Impairment

Interventions: Behavioral: Supportive Therapy
Behavioral: PATH-MCI

First Posted Date: 2017-02-06

Last Posted Date: 2025-05-20

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 80

Registration Number: NCT03043573

Locations: 🇺🇸
Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York, United States
🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

and more 1 locations

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Phase 1

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: 177Lu-PSMA-617
Drug: 68Ga-PSMA-HBED-CC

First Posted Date: 2017-02-03

Last Posted Date: 2023-11-02

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 50

Registration Number: NCT03042468

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸
Tulane Cancer Center Clinic, New Orleans, Louisiana, United States

Psychosocial Intervention for Young Children With Chronic Tics

Not Applicable

Completed

Conditions: Combined Multiple Motor and Vocal Tic Disorder
Chronic Motor and Vocal Tic Disorder
Tourette's Syndrome
Tourette's Disease
Tic Disorder, Combined Vocal and Multiple Motor
Multiple Motor and Vocal Tic Disorder, Combined
Gilles De La Tourette's Syndrome
Combined Vocal and Multiple Motor Tic Disorder
Tourette Disorder
Tourette Disease

Interventions: Behavioral: Comprehensive Behavioral Intervention for Tics (CBIT)

First Posted Date: 2017-02-03

Last Posted Date: 2019-07-30

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 15

Registration Number: NCT03042507

Impact of Duloxetine on Male Fertility

Phase 2

Completed

Conditions: Depression
Infertility, Male

Interventions: Drug: Placebo
Drug: Duloxetine

First Posted Date: 2017-02-01

Last Posted Date: 2020-03-12

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 69

Registration Number: NCT03038867

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

Phase 1

Completed

Conditions: Diffuse Large B-Cell Lymphoma
High Grade B-Cell Lymphoma

Interventions: Drug: Venetoclax
Drug: Rituximab
Drug: Etoposide
Drug: Vincristine Sulfate
Drug: Cyclophosphamide
Drug: Prednisone
Drug: Doxorubicin Hydrochloride

First Posted Date: 2017-01-30

Last Posted Date: 2022-08-24

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 31

Registration Number: NCT03036904

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 3 locations

A Pilot Study of Fear Extinction Learning in Anxious Youth

Completed

Conditions: Anxiety Disorder of Childhood

Interventions: Behavioral: Open Trial

First Posted Date: 2017-01-26

Last Posted Date: 2019-04-17

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 9

Registration Number: NCT03032926

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy